Cytokinetics (CYTK) Expected to Announce Earnings on Thursday

Key Points

• Cytokinetics (CYTK) is set to announce its Q2 2025 earnings on August 7th, with analysts predicting a loss of ($1.32) per share and revenue of $1.95 million.
• In its last earnings report for Q1 2025, Cytokinetics beat estimates with a loss of ($1.36) per share, while revenue increased 89.1% year-over-year to $1.60 million.
• The stock has a market capitalization of $4.32 billion and a consensus rating of "Moderate Buy" from analysts, with an average target price of $70.92.

Cytokinetics (NASDAQ:CYTK - Get Free Report) is anticipated to release its Q2 2025 earnings data after the market closes on Thursday, August 7th. Analysts expect Cytokinetics to post earnings of ($1.32) per share and revenue of $1.95 million for the quarter.

Cytokinetics (NASDAQ:CYTK - Get Free Report) last released its earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($1.36) earnings per share for the quarter, beating the consensus estimate of ($1.41) by $0.05. The firm had revenue of $1.60 million during the quarter, compared to the consensus estimate of $2.77 million. During the same period in the prior year, the business posted ($1.33) earnings per share. Cytokinetics's quarterly revenue was up 89.1% compared to the same quarter last year. On average, analysts expect Cytokinetics to post $-5 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Cytokinetics Stock Down 1.5%

Shares of CYTK traded down $0.56 during mid-day trading on Monday, hitting $36.13. 583,229 shares of the company's stock were exchanged, compared to its average volume of 1,749,918. The firm has a market cap of $4.32 billion, a price-to-earnings ratio of -6.81 and a beta of 0.64. The stock's 50-day simple moving average is $34.41 and its 200-day simple moving average is $39.02. Cytokinetics has a 52 week low of $29.31 and a 52 week high of $59.39.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on CYTK shares. Raymond James Financial assumed coverage on shares of Cytokinetics in a research note on Wednesday, July 30th. They issued a "market perform" rating for the company. JMP Securities restated a "market outperform" rating and issued a $78.00 price objective on shares of Cytokinetics in a research note on Thursday, April 10th. Cantor Fitzgerald upgraded Cytokinetics to a "strong-buy" rating in a research report on Tuesday, May 13th. Barclays cut their target price on Cytokinetics from $55.00 to $53.00 and set an "overweight" rating for the company in a research note on Thursday, May 8th. Finally, HC Wainwright reissued a "buy" rating and set a $120.00 price objective on shares of Cytokinetics in a research note on Monday, April 21st. Four investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $70.92.

Insider Transactions at Cytokinetics

In other Cytokinetics news, EVP Fady Ibraham Malik sold 2,000 shares of the company's stock in a transaction dated Tuesday, July 22nd. The shares were sold at an average price of $37.47, for a total transaction of $74,940.00. Following the sale, the executive vice president directly owned 140,610 shares of the company's stock, valued at approximately $5,268,656.70. This represents a 1.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Muna Bhanji sold 1,454 shares of the stock in a transaction on Thursday, May 15th. The stock was sold at an average price of $29.73, for a total transaction of $43,227.42. Following the completion of the sale, the director owned 23,510 shares in the company, valued at approximately $698,952.30. This trade represents a 5.82% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 37,749 shares of company stock valued at $1,277,937 over the last ninety days. Insiders own 2.70% of the company's stock.

Hedge Funds Weigh In On Cytokinetics

An institutional investor recently raised its position in Cytokinetics stock. Millennium Management LLC boosted its position in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 361.9% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 287,901 shares of the biopharmaceutical company's stock after acquiring an additional 225,576 shares during the period. Millennium Management LLC owned 0.24% of Cytokinetics worth $11,571,000 at the end of the most recent reporting period.

About Cytokinetics

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.